CN102219749A - Method for preparing rosuvastatin calcium - Google Patents
Method for preparing rosuvastatin calcium Download PDFInfo
- Publication number
- CN102219749A CN102219749A CN2010101463337A CN201010146333A CN102219749A CN 102219749 A CN102219749 A CN 102219749A CN 2010101463337 A CN2010101463337 A CN 2010101463337A CN 201010146333 A CN201010146333 A CN 201010146333A CN 102219749 A CN102219749 A CN 102219749A
- Authority
- CN
- China
- Prior art keywords
- compound
- reaction
- acid
- fluorophenyl
- sec
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C)C([C@]1C=CC(C[C@](C[*-])O)O)=NC(*(C)S(C)(=O)=O)=NC1c(cc1)ccc1F Chemical compound CC(C)C([C@]1C=CC(C[C@](C[*-])O)O)=NC(*(C)S(C)(=O)=O)=NC1c(cc1)ccc1F 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a preparation method of rosuvastatin calcium. The method comprises the following steps: carrying out condensation reaction on 4-(4-fluorophenyl)-6-isopropyl-2 chloropyrimidine-5-formaldehyde and (3R)-tertiary butyl dimethylsiloxo-5-oxo-6-triphenyl phosphaalkene hexanoate; and then removing a silylether protecting group of hydroxyl, carrying out stereoselectivity reduction, reacting with 2,2-dimethoxy propane, condensing with N-methyl methane sulfonamide, removing propylidene protection, hydrolyzing an ester group, salifying and carrying out other steps, so as to obtain the rosuvastatin calcium. According to the preparation method, the yield is stable, and the price of reagents is cheap; and the method is easy to operate and is beneficial to industrial production.
Description
Technical field
The present invention relates to medication preparation, be specifically related to a kind of preparation method of auspicious rosuvastatin calcium.
Background technology
The chemistry of auspicious rosuvastatin calcium is by name: (+)-(3R, 5S)-7-[4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methylsulfonyl amino) pyrimidine-5-yl]-3,5-dihydroxyl-6-(E)-heptenoic acid calcium.Chemical structural formula is:
Auspicious rosuvastatin is to be succeeded in developing by the wild adopted company of Japanese salt (Osaka Shionogi company), transfers the exploitation of AstraZeneca company and goes on the market in worldwide.Auspicious rosuvastatin is widely used as accent blood fat prescription drug owing to all have gratifying clinical effectiveness aspect drug effect and the security.
The preparation technology of auspicious rosuvastatin calcium has numerous documents and patent to report, as document (Bioorganic ﹠amp; MedicinalChemistry.vol.5.NO.2.pp.437-444.1997;) reported method; earlier synthetic important intermediate 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl N-methylsulfonyl amino) pyrimidine-5-formaldehyde and (the 3R)-tertiary butyl two silyloxies-5-oxo-6-triphenyl phosphorus alkene methyl caproate; carry out wittig reaction then; again through the silica-based protection of the demethylation tertiary butyl; sodium borohydride reduction, hydrolysis, salify obtains product.CN:1742000 and for example; WO 2004/108691 and WO2008/130678 etc. have similar approach patent WO 2009/009153 to change side chain reagent into (R)-3-tertiary butyl two silyloxies-6-(dimethoxy oxo phosphorus base)-5-oxo methyl caproate, then and 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methylsulfonyl amino) pyrimidine-5-formaldehyde carried out Ti Xi Wei-Huo Naer reaction.
The parent nucleus that patent WO 2008/044243 cuts down auspicious Soviet Union has been made phosphorus ylide reagent, and side chain has been made aldehyde, carries out wittig reaction then.
Patent WO 2005/030758 is arranged again; reports such as WO 02098854 and US 2005/0124641; side chain has been made Zhu Liya alkene reagent, then and 4-(4-fluorophenyl)-6-sec.-propyl-2-(N-methyl-N-methylsulfonyl amino) pyrimidine-5-formaldehyde carry out the reaction of Zhu Liya alkene.
Patent WO 2008044343 has made Zhu Liya alkene reagent with parent nucleus, and side chain is made aldehyde, has carried out the reaction of Zhu Liya alkene equally.
Above-mentioned patent and document all are earlier with N-methyl Toluidrin and pyrimidine ring butt joint, and then and the side chain butt joint of auspicious rosuvastatin.This series methods exists agents useful for same relatively expensive, and reaction conditions is defective such as harshness relatively.
Summary of the invention
Technical problem to be solved by this invention is to overcome above-mentioned weak point, and the research and design easy handling is easy to the preparation method of the auspicious rosuvastatin of suitability for industrialized production.
The invention provides a kind of preparation method of auspicious rosuvastatin calcium.
Reaction formula is as follows:
The inventive method comprises the following steps:
(1) 4-(4-fluorophenyl)-6-sec.-propyl-2 chloropyrimide-5-formaldehyde (compound 1) and (the 3R)-tertiary butyl two silyloxies-5-oxo-6-triphenyl phosphorus alkene capronate (the uncommon reagent of loving and respect one's elder brother Wei (compound 9)) carries out condensation reaction in organic solvent, obtain (R, E)-3-(tertiary butyl-dimethyl-silyl oxygen base)-7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-5-oxo-6-heptenoic acid esters (compound 2); The solvent of reaction is selected from toluene, benzene, acetonitrile, tetrahydrofuran (THF), normal hexane, the dioxane one or more arbitrarily than blended solvent, is preferably acetonitrile and tetrahydrofuran (THF); Temperature of reaction is 60～120 ℃, is preferably the reflux temperature of solvent; Reaction times is 5-20 hour, the preferred reaction times is the extinction time of raw material in the reaction process (compound 1), the reaction mol ratio of raw material (compound 1) and the uncommon reagent of loving and respect one's elder brother Wei (compound 9) is 1 to 0.5～3, be preferably 1 to 1～2, the R that wishes in the reagent that loves and respect one's elder brother Wei is alkyl or cycloalkyl or is benzyl, its preferable methyl, ethyl or the tertiary butyl.
(2) (R, E)-3-(tertiary butyl-dimethyl-silyl oxygen base)-7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-5-oxo-6-heptenoic acid methyl esters (compound 2) is in organic solvent, under the acidic conditions, slough the silicon ether protecting group of hydroxyl, obtain (R, E)-7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-3-hydroxyl-5-oxo-6-heptenoic acid esters (compound 3), reaction solvent is selected from methyl alcohol, ethanol, Virahol, tetrahydrofuran (THF), one or more mixed solvents in dioxane or the acetone, acid is selected from hydrochloric acid, sulfuric acid, Hydrogen bromide, hydrofluoric acid, hydroiodic acid HI, formic acid, one or more mixing acid in Glacial acetic acid or the phosphoric acid, the mole number of acid is that the 1-5 of compound 1 doubly measures, and temperature of reaction is controlled at 10-25 ℃;
(3) in the presence of organoboron reagent, (R, E)-7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-3-hydroxyl-5-oxo-6-heptenoic acid methyl esters (compound 3), in the process organic solvent of no water treatment, reductive agent exists down, and the Stereoselective reduction obtains (3R, 5S, E)-and 7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-3,5-dihydroxyl-6-heptenoic acid methyl esters (compound 4); Reaction solvent is the tetrahydrofuran (THF)/anhydrous methanol of no water treatment (v/v=4: mixed solvent 1) or do not have tetrahydrofuran (THF)/dehydrated alcohol (v/v=4: mixed solvent 1) of water treatment; Organoboron reagent is selected from one or more in trimethyl-boron, triethyl-boron, diethyl methoxyl group boron, trimethoxy-boron or the triethoxy-boron, and the amount of organoboron reagent is 1.0-1.5 a times of compound 3 molar weights, is preferably 1.0 times of molar weights; Temperature of reaction is controlled at 0 ℃--80 ℃, be preferably-40 ℃--and 60 ℃; Reductive agent is sodium borohydride or POTASSIUM BOROHYDRIDE, and the amount of reductive agent is a 1.0-4.0 times of molar weight of compound 3
(4) under the catalysis of acid, (3R, 5S, E)-7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-3,5-dihydroxyl-6-heptenoic acid methyl esters (compound 4) and 2 of 1.0-5.0 times of molar weight, the 2-Propanal dimethyl acetal reacts, obtain (3R, 5S, E)-7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-2,2-dimethyl-3,5 dioxy alkane-6-heptenoic acid methyl esters (compound 5); 2, the 2-Propanal dimethyl acetal be reaction solvent also be reaction reagent; Acid is selected from one or more in tosic acid, Phenylsulfonic acid or the sal enixum, and the consumption of acid is the 0.01-0.1 molar weight doubly of compound 4, and temperature of reaction is controlled at 10-25 ℃ of reaction;
(5) (3R, 5S, E)-7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-2,2-dimethyl-3, the N-methyl Toluidrin of 5 dioxies alkane-6-heptenoic acid methyl esters (compound 5) and 1.0-5.0 times of molar weight, in the presence of organic bases or mineral alkali, carry out condensation reaction, obtain (3R, 5S, E)-7-(2-(N-methyl methylsulfonyl amido)-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-2,2-dimethyl-3,5 dioxies alkane-6-heptenoic acid methyl esters (compound 6), reaction solvent is selected from methyl-sulphoxide, N, dinethylformamide, N-Methyl pyrrolidone; Organic bases is selected from diisopropyl ethyl amine, N, N-dimethyl aminopyridine, triethylamine, 1, one or more in 8-diazacyclo [5,4,0]-11 carbon-7-alkene; Mineral alkali is selected from one or more in yellow soda ash, salt of wormwood or the cesium carbonate; The amount of organic bases and mineral alkali is a 1.0-5.0 times of molar weight of compound 5, is preferably 1.0-2.0 times of molar weight; Temperature of reaction is controlled at 60 ℃-120 ℃, is preferably 80 ℃-100 ℃; Reaction times is 5-20 hour;
(6) in organic solvent, (3R, 5S, E)-and 7-(2-(N-methyl methylsulfonyl amido)-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-2,2-dimethyl-3,5 dioxy alkane-6-heptenoic acid methyl esters (compound 6) takes off the propylidene protection under acidic conditions; Then, compound 7 is without separation, hydrolysis ester group under alkaline condition, obtain (3R, 5S, E)-and 7-(2-(N-methyl methylsulfonyl amido)-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-3,5 dihydroxyl-6-heptenoic acid (compound 8), reaction solvent is selected from one or more mixed solvents in methyl alcohol, ethanol, Virahol, tetrahydrofuran (THF), dioxane or the acetone; Acid is selected from one or more mixing acid in hydrochloric acid, sulfuric acid, Hydrogen bromide, hydrofluoric acid, hydroiodic acid HI, formic acid or the phosphoric acid; The amount of acid is a 1.0-3.0 times of molar weight of compound 6, is preferably 1.0-1.5 times of molar weight; Alkali is selected from one or more the mixture of any ratio of the oxyhydroxide of basic metal or alkaline-earth metal or oxide compound, and the amount of alkali is a 2.0-6.0 times of molar weight of compound 6, is preferably 2.0-3.0 times of molar weight; 10 ℃-25 ℃ of temperature of reaction, the reaction times is 4-8 hour.；
(7) compound 8 and inorganic calcium salt salify obtain the auspicious rosuvastatin calcium of target product; Reaction solvent is a water, and inorganic calcium salt is selected from calcium chloride, calcium lactate; Temperature of reaction is 10 ℃-25 ℃, and the reaction times is 5.0-10.0 hour.
Preparation method of the present invention, each goes on foot stable yield, the reagent low price, easy handling is suitable for the realization suitability for industrialized production.
Embodiment
Embodiment 1:
(R, E)-preparation of 3-(tertiary butyl-dimethyl-silyl oxygen base)-7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-5-oxo-6-heptenoic acid methyl esters (compound 2).
Reaction formula:
Operation steps:
In the 1L single port bottle, add 20 and digest compound 1,58 gram phosphorus ylide reagent and 500mL anhydrous acetonitriles, be heated to back flow reaction 20 hours, the TLC monitoring reaction is complete, and 30 ℃ of water-baths are revolved to steam to remove and desolvated, resistates is washed through twice 20 milliliters of sherwood oils, get 28.8 and digest compound, be directly used in the next step, yield 74.95%.
1HNMR(300MHz，CDCl
3)：δ0.01(6H，d)，0.78(6H，s)，1.26(6H，dd，J＝6.69Hz)，2.47(2H，m)，2.74(2H，dd，J＝6.02Hz)，3.3(1H，m)，3.65(3H，s)，4.58(1H，m)，6.19(1H，dd，J＝16.42Hz)，7.11(2H，m)，7.56(3H，m)。
MS(ESI)m/z：535(M+H)，557(M+Na)。
Embodiment 2:
(R, E)-preparation of 7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-3-hydroxyl-5-oxo-6-heptenoic acid methyl esters (compound 3).
Reaction formula:
Operation steps:
In the 500mL single port bottle, add 18 gram formulas, 2 compounds, the 30mL tetrahydrofuran (THF), 90mL Glacial acetic acid and 30mL water are heated to 40 ℃ of reactions 24 hours, and the TLC monitoring reaction is complete, 150 milliliters of ethyl acetate are divided three extractions, and oil reservoir merges, water washing, the TLC monitoring, saturated common salt water washing, anhydrous sodium sulfate drying, filter, 30 ℃ of water-baths are revolved to steam to remove and are desolvated, and get 13.45 and digest compound 3, can be directly used in the next step, yield 95%.
1HNMR(300MHz，CDCl
3)：δ1.29(6H，dd，J＝6.7Hz)，2.52(2H，dd，J＝6.32Hz)，2.72(2H，m)，3.34(1H，m)，3.7(3H，s)，4.46(1H，m)，6.20(1H，dd，J＝16.42Hz)，7.09-7.15(2H，m)，7.53～7.60(3H，m)。
Embodiment 3:
(3R, 5S, E)-and 7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-3, the preparation of 5-dihydroxyl-6-heptenoic acid methyl esters (compound 4).
Reaction formula:
Operation steps:
In the 2000mL there-necked flask; under the argon shield, add 24.2 gram formulas, 3 compounds, the 650mL anhydrous tetrahydro furan; the 170mL anhydrous methanol; be cooled to-50 ℃, add the diethyl methoxyl group borane reagent of 12.2 grams 50%, reacted 0.5 hour; add 2.67 gram sodium borohydrides; controlled temperature is at-40 ℃--and 60 ℃ were reacted 3 hours, and the TLC monitoring reaction is complete, added 33mL Glacial acetic acid cancellation reaction; with about saturated aqueous sodium carbonate adjust pH to 8; 240 milliliters of ethyl acetate are divided three extractions, and oil reservoir merges, water washing; the TLC monitoring; the saturated common salt water washing, anhydrous sodium sulfate drying filters; 30 ℃ of water-baths are revolved to steam to remove and are desolvated; get 24 gram formulas, 4 compounds, resistates can be directly used in the next step, yield 98.70%.
1HNMR(300MHz，CDCl
3：δ1.27(7H，m)，1.93(1H，m)，2.42(1H，dd，J＝15.67，6.59Hz)，2.62(1H，dd，J＝15.7，6.69Hz)，3.32(1H，m)，3.70(3H，s)，4.39(1H，m)，4.50(1H，m)，5.50(1H，dd，J＝16.08，4.69Hz)，6.63(1H，dd，J＝16.07，1.61Hz)，7.08(2H，m)，7.59(2H，m)。
Embodiment 4:
(3R, 5S, E)-and 7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-2, the preparation of 2-dimethyl-3,5 dioxy alkane-6-heptenoic acid methyl esters (compound 5).
Reaction formula:
Operation steps:
20 gram formulas, 4 compounds are dissolved in 200mL2, in the 2-Propanal dimethyl acetal, add 1.2 gram tosic acid, 10-25 ℃ of reaction spent the night, and the TLC monitoring reaction is complete, and 30 ℃ of water-baths are revolved to steam to remove and desolvated, resistates is with 100 milliliters of acetic acid ethyl dissolutions, 50 milliliters of moisture are washed for three times, and anhydrous sodium sulfate drying filters, 30 ℃ of water-baths are revolved to steam to remove and are desolvated, get 20.8 gram formulas, 5 compounds, can be directly used in the next step, yield 95.0%.
1HNMR(300MHz，CDCl
3)：δ1.16(14H，m)，2.36(1H，dd，J＝15.74，6.43Hz)，2.55(1H，dd，J＝15.69，6.75Hz)，3.34(1H，m)，3.68(3H，s)，4.36(2H，m)，5.49(1H，dd，J＝16.27，5.11Hz)，6.49(1H，dd，J＝16.26Hz)，7.08(2H，m)，7.58(2H，m)。
Embodiment 5:
(3R, 5S, E)-and 7-(2-(N-methyl methylsulfonyl amido)-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-2, the preparation of 2-dimethyl-3,5 dioxy alkane-6-heptenoic acid methyl esters (compound 6).
Reaction formula:
Operation steps:
7.5 gram formula 5 compounds are dissolved in the 100mL anhydrous dimethyl sulfoxide, add 5.3 gram N-methyl Toluidrins, 2.7 gram Anhydrous potassium carbonates, 90～100 ℃ were reacted 10 hours, and the TLC monitoring reaction is complete, and 120 milliliters of ethyl acetate are divided three extractions, oil reservoir merges, the saturated common salt water washing, anhydrous sodium sulfate drying filters, 30 ℃ of water-baths are revolved to steam to remove and are desolvated, resistates gets 4.28 gram formulas, 6 compounds, yield 49.30% through 20 milliliters of recrystallizations of anhydrous methanol.
1HNMR(300MHz，CDCl
3)：δ1.16(14H，m)，2.27(1H，dd，J＝15.33，6.35Hz)，2.43(1H，dd，J＝15.34，6.82Hz)，3.34(1H，m)，3.50(3H，s)，3.55(3H，s)，3.68(3H，s)，4.42(2H，m)，4.40(2H，m)，5.45(1H，dd，J＝16.24，5.15Hz)，6.50(1H，dd，J＝16.26Hz)，7.06(2H，m)，7.63(2H，m)。
Embodiment 6:
(3R, 5S, E)-preparation of 7-(2-(N-methyl methylsulfonyl amido)-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-3,5 dihydroxyl-6-heptenoic acid (compound 8).
Reaction formula:
Operation steps:
2.0 gram formula 6 compounds are dissolved in the 20mL tetrahydrofuran (THF), the HCl aqueous solution that adds 5mL2mol/L, 10-25 ℃ of reaction spent the night, and TLC monitoring reaction to formula 6 compounds disappear, ice-water bath is chilled to 0-5 ℃, drip 8.8ml 2mol/L lithium hydroxide aqueous solution, add 2mL methyl alcohol, temperature control is 10-25 ℃ of reaction, TLC monitors to formula 7 compounds and disappears, 30 ℃ remove tetrahydrofuran (THF) and methyl alcohol under reduced pressure, add the dilution of 20mL water, the 20mL extracted with diethyl ether, the water ice-water bath is cooled to 0-5 ℃, the HCl aqueous solution with 2mol/L is transferred pH to 3.0～4.0,3 * 20mL extracted with diethyl ether, merges organic phase, anhydrous sodium sulfate drying, filter, 30 ℃ remove solvent under reduced pressure, get (3R, 5S, E)-and 7-(2-(N-methyl methylsulfonyl amido)-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-3,5 dihydroxyl-6-heptenoic acid 1.71 grams, yield 95.10%.
Embodiment 7,
Become the calcium salt reaction:
Reaction formula:
Operation steps:
Embodiment 6 gained compounds 1.71 grams are dissolved in the NaOH aqueous solution of 3.6mL1mol/L, add the 5mL deionized water, add the 400mg Calcium Chloride Powder Anhydrous, room temperature 10-25 ℃, reacted 5 hours, filter, the small amount of deionized water washing, 50 ℃ of temperature controls vacuumize (5 mmhg) oven dry, get 1.60 gram products, yield 90%.
Claims (8)
1. the preparation method of an auspicious rosuvastatin calcium is characterized in that this method comprises the following steps:
Reaction formula is as follows:
(1) 4-(4-fluorophenyl)-6-sec.-propyl-2 chloropyrimide-5-formolation compound 1 and (the 3R)-tertiary butyl two silyloxies-5-oxo-6-triphenyl phosphorus alkene capronate compound 9 carries out condensation reaction in organic solvent, obtain (R, E)-3-(tertiary butyl-dimethyl-silyl oxygen base)-7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-5-oxo-6-heptenoic acid esters compound 2;
(2) (R, E)-3-(tertiary butyl-dimethyl-silyl oxygen base)-7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-5-oxo-6-heptenoic acid methyl esters (compound 2) is in organic solvent, under the acidic conditions, slough the silicon ether protecting group of hydroxyl, obtain (R, E)-7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-3-hydroxyl-5-oxo-6-heptenoic acid esters compound 3;
(3) in the presence of organoboron reagent, (R, E)-7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-3-hydroxyl-5-oxo-6-heptenoic acid methyl esters (compound 3) is in the organic solvent of no water treatment, reductive agent exists down, the Stereoselective reduction obtains (3R, 5S, E)-7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-3,5-dihydroxyl-6-heptenoic acid methyl compound 4;
(4) under the catalysis of acid, (3R, 5S, E)-7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-3,5-dihydroxyl-6-heptenoic acid methyl esters (compound 4) and 2 of 1.0-5.0 times of molar weight, the 2-Propanal dimethyl acetal reacts, obtain (3R, 5S, E)-7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-2,2-dimethyl-3,5 dioxy alkane-6-heptenoic acid methyl compound 5;
(5) (3R, 5S, E)-7-(2-chloro-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-2, the N-methyl Toluidrin of 2-dimethyl-3,5 dioxy alkane-6-heptenoic acid methyl esters (compound 5) and 1.0-5.0 times of molar weight carries out condensation reaction in the presence of organic bases and mineral alkali, obtain (3R, 5S, E)-and 7-(2-(N-methyl methylsulfonyl amido)-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-2,2-dimethyl-3,5 dioxy alkane-6-heptenoic acid methyl compound 6;
(6) in organic solvent, (3R, 5S, E)-and 7-(2-(N-methyl methylsulfonyl amido)-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-2, under 2-dimethyl-3,5 dioxy alkane-6-heptenoic acid methyl esters (compound 6) acidic conditions, take off the propylidene protection; Then, compound 7 is without separation, hydrolysis ester group under alkaline condition, obtain (3R, 5S, E)-7-(2-(N-methyl methylsulfonyl amido)-4-(4-fluorophenyl)-6-sec.-propyl-pyrimidine-5-yl)-3,5 dihydroxyl-6-heptenoic acid compound 8;
(7) compound 8 and inorganic calcium salt salify obtain auspicious rosuvastatin calcium.
2. the preparation method of a kind of auspicious rosuvastatin calcium according to claim 1, it is characterized in that, the solvent of described step (1) reaction is selected from one or more blended solvents in toluene, benzene, acetonitrile, tetrahydrofuran (THF), normal hexane, the dioxane, is preferably acetonitrile or tetrahydrofuran (THF); Temperature of reaction is 60～120 ℃, is preferably the reflux temperature of solvent; Reaction times is 5-20 hour, and the preferred reaction times is the extinction time of starting compound 1 in the reaction process; The reaction mol ratio of compound 1 and compound 9 is 1 to 0.5～3, is preferably 1 to 1～2; R in the compound 9 is alkyl, cycloalkyl or benzyl, preferable methyl, ethyl or the tertiary butyl.
3. the preparation method of a kind of auspicious rosuvastatin calcium according to claim 1, it is characterized in that, described step (2) reaction solvent is selected from one or more mixed solvents in methyl alcohol, ethanol, Virahol, tetrahydrofuran (THF), dioxane or the acetone, described acid is selected from one or more mixing acid in hydrochloric acid, sulfuric acid, Hydrogen bromide, hydrofluoric acid, hydroiodic acid HI, formic acid, Glacial acetic acid or the phosphoric acid, the mole number of acid is that the 1-5 of compound 1 doubly measures, and temperature of reaction is controlled at 10-25 ℃.
4. the preparation method of a kind of auspicious rosuvastatin calcium according to claim 1, it is characterized in that described step (3) reaction solvent is anhydrous tetrahydro furan/anhydrous methanol v/v=4: 1 mixed solvent or anhydrous tetrahydro furan/dehydrated alcohol v/v=4: 1 mixed solvent; Described organoboron reagent is selected from one or more in trimethyl-boron, triethyl-boron, diethyl methoxyl group boron, trimethoxy-boron or the triethoxy-boron, the amount of organoboron reagent be compound 3 molar weight 1.0-1.5 doubly, be preferably 1.0 times of molar weights; Temperature of reaction is controlled at 0 ℃--80 ℃, be preferably-40 ℃--and 60 ℃; Described reductive agent is sodium borohydride or POTASSIUM BOROHYDRIDE, and the amount of reductive agent is a 1-4 times of molar weight of compound 3;
5. the preparation method of a kind of auspicious rosuvastatin calcium according to claim 1 is characterized in that, the reaction solvent of described step (4) is reaction reagent 2, the 2-Propanal dimethyl acetal; Described acid is selected from one or more in tosic acid, Phenylsulfonic acid or the sal enixum, and the consumption of acid is the 0.01-0.1 molar weight doubly of compound 4, and temperature of reaction is controlled at 10-25 ℃ of reaction.
6. the preparation method of a kind of auspicious rosuvastatin calcium according to claim 1 is characterized in that, the reaction solvent of described step (5) is selected from methyl-sulphoxide, N, dinethylformamide, N-Methyl pyrrolidone; Described organic bases is selected from diisopropyl ethyl amine, N, N-dimethyl aminopyridine, triethylamine or 1, one or more in 8-diazacyclo [5,4,0]-11 carbon-7-alkene; Described mineral alkali is selected from one or more in yellow soda ash, salt of wormwood or the cesium carbonate; The amount of organic bases or mineral alkali is a 1.0-5.0 times of molar weight of compound 5, is preferably 1.0-2.0 times of molar weight; Temperature of reaction is controlled at 60 ℃-120 ℃, is preferably 80 ℃-100 ℃; Reaction times is 5-20 hour.
7. the preparation method of a kind of auspicious rosuvastatin calcium according to claim 1 is characterized in that, the reaction solvent of described step (6) is selected from one or more mixed solvents in methyl alcohol, ethanol, Virahol, tetrahydrofuran (THF), dioxane or the acetone; Described acid is selected from one or more mixing acid in hydrochloric acid, sulfuric acid, Hydrogen bromide, hydrofluoric acid, hydroiodic acid HI, formic acid or the phosphoric acid; The amount of acid is a 1.0-3.0 times of molar weight of compound 6, is preferably 1.0-1.5 times of molar weight; Described alkali is selected from the oxyhydroxide of basic metal or alkaline-earth metal or one or more the mixture in the oxide compound, and the amount of alkali is a 2.0-6.0 times of molar weight of compound 6, is preferably 2.0-3.0 times of molar weight; 10 ℃-25 ℃ of temperature of reaction, the reaction times is 4-8 hour.
8. the preparation method of a kind of auspicious rosuvastatin calcium according to claim 1 is characterized in that, the solvent of described step (7) is a water; Described inorganic calcium salt is selected from calcium chloride or calcium lactate; Temperature of reaction is 10 ℃-25 ℃, and the reaction times is 5.0-10.0 hour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101463337A CN102219749B (en) | 2010-04-14 | 2010-04-14 | Method for preparing rosuvastatin calcium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101463337A CN102219749B (en) | 2010-04-14 | 2010-04-14 | Method for preparing rosuvastatin calcium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102219749A true CN102219749A (en) | 2011-10-19 |
| CN102219749B CN102219749B (en) | 2013-07-17 |
Family
ID=44776480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101463337A Active CN102219749B (en) | 2010-04-14 | 2010-04-14 | Method for preparing rosuvastatin calcium |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102219749B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103864701A (en) * | 2014-03-10 | 2014-06-18 | 常熟市金申医化制品有限责任公司 | Preparation method of 4-sulfanilamide-5-methoxyl-6-chloropyrimidine |
| CN104031099A (en) * | 2014-06-30 | 2014-09-10 | 济南卡博唐生物科技有限公司 | Method for catalyzing propylidene removal of dual-propylidene sugar compound |
| CN111718334A (en) * | 2019-03-20 | 2020-09-29 | 鲁南制药集团股份有限公司 | Rosuvastatin calcium intermediate compound |
| CN113831295A (en) * | 2021-09-26 | 2021-12-24 | 江苏福瑞康泰药业有限公司 | Method for synthesizing rosuvastatin ester by using continuous flow tubular reactor |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05178841A (en) * | 1991-07-01 | 1993-07-20 | Shionogi & Co Ltd | Pyrimidine derivative |
| CN1898233A (en) * | 2003-10-24 | 2007-01-17 | 阿斯利康(英国)有限公司 | Process for the manufacture of the calcium salt of rosuvatatin (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and crystallin |
| WO2009009153A1 (en) * | 2007-07-12 | 2009-01-15 | Teva Pharmaceutical Industries Ltd. | Purification of rosuvastatin intermediate by thin film evaporation and chemical method |
| WO2009157014A2 (en) * | 2008-01-30 | 2009-12-30 | Cadila Healthcare Limited | A process for preparing hmg-coa reductase inhibitors and intermediates |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5178841B2 (en) * | 2008-10-29 | 2013-04-10 | 三菱電機株式会社 | Air conditioner |
-
2010
- 2010-04-14 CN CN2010101463337A patent/CN102219749B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05178841A (en) * | 1991-07-01 | 1993-07-20 | Shionogi & Co Ltd | Pyrimidine derivative |
| CN1898233A (en) * | 2003-10-24 | 2007-01-17 | 阿斯利康(英国)有限公司 | Process for the manufacture of the calcium salt of rosuvatatin (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid and crystallin |
| WO2009009153A1 (en) * | 2007-07-12 | 2009-01-15 | Teva Pharmaceutical Industries Ltd. | Purification of rosuvastatin intermediate by thin film evaporation and chemical method |
| WO2009157014A2 (en) * | 2008-01-30 | 2009-12-30 | Cadila Healthcare Limited | A process for preparing hmg-coa reductase inhibitors and intermediates |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103864701A (en) * | 2014-03-10 | 2014-06-18 | 常熟市金申医化制品有限责任公司 | Preparation method of 4-sulfanilamide-5-methoxyl-6-chloropyrimidine |
| CN103864701B (en) * | 2014-03-10 | 2016-08-24 | 常熟市金申医化制品有限责任公司 | The preparation method of 4-sulfanilamide-5-methoxyl group-6-chloropyrimide |
| CN104031099A (en) * | 2014-06-30 | 2014-09-10 | 济南卡博唐生物科技有限公司 | Method for catalyzing propylidene removal of dual-propylidene sugar compound |
| CN104031099B (en) * | 2014-06-30 | 2016-03-02 | 济南尚博生物科技有限公司 | A kind of sugar compounds containing two propylidene base takes off the catalysis process of propylidene |
| CN111718334A (en) * | 2019-03-20 | 2020-09-29 | 鲁南制药集团股份有限公司 | Rosuvastatin calcium intermediate compound |
| CN111718334B (en) * | 2019-03-20 | 2022-09-30 | 鲁南制药集团股份有限公司 | Rosuvastatin calcium intermediate compound |
| CN113831295A (en) * | 2021-09-26 | 2021-12-24 | 江苏福瑞康泰药业有限公司 | Method for synthesizing rosuvastatin ester by using continuous flow tubular reactor |
| CN113831295B (en) * | 2021-09-26 | 2024-03-19 | 江苏福瑞康泰药业有限公司 | Method for synthesizing rosuvastatin ester by using continuous flow tubular reactor |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102219749B (en) | 2013-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102219749B (en) | Method for preparing rosuvastatin calcium | |
| EP3080086A1 (en) | Process of making adamantanamides | |
| CN102675306A (en) | Preparing method of moxifloxacin or slat thereof | |
| CN104030989A (en) | Preparation method of rosuvastatin calcium | |
| CN104003934B (en) | The synthesis of the fluoro-2-pyridine carboxylic acid of the chloro-3-of 6- | |
| CN106831756B (en) | A kind of high-purity high-yield is suitble to the aclidinium bromide preparation method of industrialized production | |
| CN103508934A (en) | Preparation method of gliclazide | |
| CN106928226A (en) | A kind of preparation method of doxofylline | |
| CN104130128A (en) | Synthetic method of phenoxyl acetate and intermediate thereof | |
| CN112250620A (en) | Synthesis method of pirfenidone | |
| CN103373995B (en) | A kind of method preparing Malaridine | |
| CN101508662A (en) | Solvent-free phase transfer catalysis synthesis method of sec-butyl disulfide | |
| CN105884807A (en) | Pinacol borate derivative preparation method and thioacetate compound preparation method | |
| CN102180843A (en) | Preparation method of 2-(2-amino-4-thiazolyl)-2(Z)-triphenylmethoxy imidoacetic acid | |
| CN102153522B (en) | Novel method for preparing N-substituted 2-hydroxy-morpholin-3-one compound | |
| CN108530476A (en) | A kind of preparation method of gram of vertical boron sieve intermediate | |
| WO2022199378A1 (en) | Synthetic method of bempedoic acid active pharmaceutical ingredient | |
| CN109988108A (en) | A kind of rich preparation method for Buddhist nun of card | |
| CN104672180B (en) | Chiral preparation method of [(1S)-3-methyl-1-[[(2R)-2-methylepoxyethyl]carbonyl]butyl]tert-butyl carbamate | |
| JP2017508790A (en) | Intermediate compound for producing rosuvastatin calcium and method for producing rosuvastatin calcium using the same | |
| CN103183680A (en) | Method for preparing asenapine | |
| CN102076657A (en) | Process for production of mandelonitrile compound | |
| CN105061209A (en) | Synthetic method of 2-diester methylmalonate compounds | |
| CN102010325A (en) | Method for synthesizing p-hydroxyphenylacetic acid | |
| CN105085278A (en) | Method for preparing 2-methyl-1-substituted phenyl-2-propyl amine compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: SHANGHAI JINGXIN BIOLOGICAL MEDICAL CO., LTD. Effective date: 20140213 |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201210 PUDONG NEW AREA, SHANGHAI TO: 312500 SHAOXING, ZHEJIANG PROVINCE |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140213 Address after: 312500 Zhejiang County of Xinchang province habayashi street Xinchang Avenue Road No. 800 Patentee after: Zhejiang Jingxin Pharmaceutical Co., Ltd. Address before: Shanghai city 201210 libing road Pudong New Area Zhangjiang hi tech Park No. 306 Patentee before: Shanghai Jingxin Biological Medical Co., Ltd. |